{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:05:07Z","timestamp":1792029907697,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.eprac.2025.04.021","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T19:43:31Z","timestamp":1746474211000},"page":"995-1001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Diagnostic Performance of Noninvasive Tests for Identifying Advanced Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease With Mixed Etiologies"],"prefix":"10.1016","volume":"31","author":[{"given":"He","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxuan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hekai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2025.04.021_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.eprac.2025.04.021_bib2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2025.04.021_bib3","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.021_bib4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.eprac.2025.04.021_bib5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cac2.12454","article-title":"Differential risk of 23 site-specific incident cancers and cancer-related mortality among patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects","volume":"43","author":"Chung","year":"2023","journal-title":"Cancer Commun (Lond)"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.021_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2021.09.030","article-title":"Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus","volume":"76","author":"Mallet","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.021_bib7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ueg2.12524","article-title":"Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease","volume":"12","author":"Hagstr\u00f6m","year":"2024","journal-title":"United Eur Gastroenterol J"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.021_bib8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","article-title":"Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B","volume":"73","author":"Mak","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.021_bib9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/hep.20519","article-title":"Impact of steatosis on progression of fibrosis in patients with mild hepatitis C","volume":"41","author":"Fartoux","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.021_bib10","first-page":"128","article-title":"Metabolic dysfunction-associated fatty liver disease (MAFLD) and viral hepatitis","volume":"10","author":"Wang","year":"2022","journal-title":"J Clin Transl Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2025.04.021_bib11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.021_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but No other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.eprac.2025.04.021_bib13","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/apm.12742","article-title":"Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study","volume":"125","author":"Rastogi","year":"2017","journal-title":"Apmis"},{"issue":"5","key":"10.1016\/j.eprac.2025.04.021_bib14","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2020.11.050","article-title":"Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease","volume":"74","author":"Papatheodoridi","year":"2021","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.021_bib15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2468-1253(16)30081-4","article-title":"Screening for liver fibrosis in the general population: a call for action","volume":"1","author":"Gin\u00e8s","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.021_bib16","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1053\/j.gastro.2023.05.053","article-title":"Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China","volume":"165","author":"Man","year":"2023","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.021_bib17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.021_bib18","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.021_bib19","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.021_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.021_bib21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.eprac.2025.04.021_bib22","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2337\/dc22-2048","article-title":"High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold","volume":"46","author":"Castera","year":"2023","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2025.04.021_bib23","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2337\/dc22-0556","article-title":"Noninvasive fibrosis screening in fatty liver disease among vulnerable populations: impact of diabetes and obesity on FIB-4 score accuracy","volume":"45","author":"Kim","year":"2022","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2025.04.021_bib24","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cgh.2022.02.059","article-title":"Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications","volume":"21","author":"Boursier","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.021_bib25","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cgh.2022.05.015","article-title":"Poor diagnostic efficacy of noninvasive tests for advanced fibrosis in obese or younger than 60 diabetic NAFLD patients","volume":"21","author":"Ito","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2025.04.021_bib26","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.021_bib27","first-page":"222","article-title":"A novel algorithm for streamlining diagnosis of advanced liver fibrosis in CHB patients with concurrent hepatic steatosis","volume":"12","author":"Xu","year":"2024","journal-title":"J Clin Transl Hepatol"},{"issue":"11","key":"10.1016\/j.eprac.2025.04.021_bib28","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population","volume":"20","author":"Graupera","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.021_bib29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cld.2013.09.006","article-title":"The impact of obesity and metabolic syndrome on alcoholic liver disease","volume":"18","author":"Chiang","year":"2014","journal-title":"Clin Liver Dis"},{"issue":"9","key":"10.1016\/j.eprac.2025.04.021_bib30","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.cgh.2018.01.026","article-title":"Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis","volume":"16","author":"Ajmera","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.eprac.2025.04.021_bib31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/01.mcg.0000135372.10846.2a","article-title":"Obesity and non-alcoholic fatty liver disease in chronic hepatitis C","volume":"38","author":"Younossi","year":"2004","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"10.1016\/j.eprac.2025.04.021_bib32","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/gut.2010.228262","article-title":"Insulin resistance and hepatitis C: an evolving story","volume":"60","author":"Eslam","year":"2011","journal-title":"Gut"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25001405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25001405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T19:07:35Z","timestamp":1756753655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25001405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1530891X25001405"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.04.021","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic Performance of Noninvasive Tests for Identifying Advanced Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease With Mixed Etiologies","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}